Molecular-immunohistochemical characteristics of proliferation and apoptosis of tumor cells in colorectal adenocarcinoma
DOI:
https://doi.org/10.14739/2310-1237.2018.1.129447Keywords:
colorectal cancer, immunohistochemistry, K-RAS geneAbstract
Aim – to study the features of K-RAS transcriptional activity gene, Ki-67 and TP53 mRNA genes expression levels in comparison with the immunohistochemical expression levels of Ki-67, p53 proteins and caspase-3 encoded by them in colorectal adenocarcinoma (CRA) with its progression from the I to the IV stage.
Materials and methods. Parallel immunohistochemical and molecular-genetic, pathohistological studies of operational material of CRA from 40 patients (4 study groups – I, II, III, IV stages of the disease according to pTNM classification – 10 cases in each group) with diagnosis of colorectal adenocarcinoma, and also sectional material of 10 fragments of distal colonic wall with normal histological structure were conducted.
Results. In comparison with unchanged mucosa of distal colon, CRA is characterized by the increased K-RAS gene and Ki-67 gene activity. As CRA progresses from the I to IV stages, there is an increase in the transcriptional activity of the K-RAS gene and a decrease in the transcriptional activity of the Ki-67 gene in the study groups. The tumor cells are characterized by the medium level of expression of Ki-67, which is the marker of cellular proliferation, herewith the reverse correlation between the Ki-67 expression level and the tumor invasion level is present. CRA is characterized by the increased TP53 gene transcriptional activity with the tendency to elevation, which happens during the progression of the tumor from the I to the IV stage and correlates with the increased K-RAS gene transcriptional activity. CRA is also characterized by the medium p53 expression level and the low level of caspase-3 expression, which is the marker of apoptotic degradation process, which happens in the presence of the reverse correlation between the increased K-RAS gene transcriptional activity and the low level of apoptosis of the tumor cells.
Conclusions. The K-RAS and TP53 genes transcriptional activity increases, but the Ki-67 gene transcriptional activity decreases during the process of CRA progression from the I to the IV stage. The inverse correlation between the level of transcription activity of the K-RAS, TP53 genes and apoptosis of tumor cells of the colorectal adenocarcinoma was determined. The decline of proliferation level of the tumor cells, that is observed during the process of CRA progression from the I to the IV stage, is mediated by the signal pathways, which don’t have connection with RAS-protein.
References
Fedorenko, Z. P., Hulak, L. O., Mykhailovych, Yu. Y., Horokh, Ye. L., Ryzhov, A. U., Sumkina, O. V., & Kutsenko, L. B. (2017) Zakhvoriuvanist ta smertnist vid zloiakisnykh novoutvoren. Stan onkolohichnoi dopomohy naselenniu. Rak v Ukraini, 2015–2016: biuleten natsionalnoho kantser-reiestru Ukrainy, 18. [in Ukrainian].
Arvelo, F., Sojo, F., Cotte, C. (2015) Biology of colorectal cancer. Ecancermedicalscience, 9, 520-534.
Boutin, A. T., Liao, W. T., Wang, M., Hwang S. S., Karpinets, T. V., Cheung, H., Chu, G. C., Jiang, S., Hu, J., Chang, K., Vilar, E., Song, X., Zhang, J., Kopetz, S., Futreal, A., Wang, Y. A., Kwong, L. N., DePinho, R. A. (2017) Oncogenic Kras drives invasion and maintains metastases in colorectal cancer. Genes & Development, 31 (4), 370-382.
Margetis, N., Kouloukoussa, M., Pavlou, K., Vrakas, S., Mariolis-Sapsakos, T. (2017) K-ras Mutations as the Earliest Driving Force in a Subset of Colorectal Carcinomas. In vivo, 31 (4), 527-542.
Kwak, M. S., Cha, J. M., Yoon, J. Y., Jeon, J. W., Shin, H. P., Chang, H. J., Kim, H. H., Joo, K. R., Lee, J. I. (2017) Prognostic value of KRAS codon 13 gene mutation for overall survival in colorectal cancer: Direct and indirect comparison meta-analysis. Medicine (Baltimore), 96 (35), E7882.
van Helden, E. J., Menke-van der Houven van Oordt, C. W., Heymans, M. W., Ket, J. C. F., Verheul, H. M. W. (2017) Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis. Cancer metastasis reviews, 36 (2), 395-406.
Loree, J. M., Kopetz, S. (2017) Recent developments in the treatment of metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 9 (8), 551-564.
Xiuli, L., Jakubowski, M., Hunt, J. L. (2015) KRAS Gene Mutation in Colorectal Cancer Is Correlated With Increased Proliferation and Spontaneous Apoptosis. American Journal of Clinical Pathology, 135 (2), 245-252.
Coulson, R. (2015) Molecular Profiling in Resectable Colorectal Liver Metastases: The Role of KRAS Mutation Status in Assessing Prognosis in the Preoperative Setting. Journal of the advanced practitioner of oncology, 6 (5), 470-474.
Temraz, S., Mukherji, D., Shamseddine, A. (2015) Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers. International Journal of Molecular Sciences, 16 (19), 22976-22988.
Sobin, L. H., Gospodarowicz, M. K., Wittekind, C. International Union Against Cancer (UICC): TNM Classification of Malignant Tumours. New York: Wiley-Blackwell, 2009, 50 pp.
Uhlén, M. (2015) The Human Protein Atlas. URL: http://www.proteinatlas.org.
Tumanskyi, V. O., Yevsieiev, A. V., Kovalenko, I. S., & Zubko, M. D. (patentee) (2015) Patent 99314 Ukraina, MPK 2015.01 G01N 21/00 G06K 9/00 Sposib fototsyfrovoi morfometrii imunohistokhimichnykh preparativ [Patent of Ukraine 99314, IPC 2015.01 G01N 21/00 G06K 9/00 The technique of digital morphometry of immunohistochemical slides]. Biuleten, 10 [in Ukrainian].
Shyshkin, M., A. (2016) Sravnitelnaya immunogistohimicheskaya harakteristika proliferatsii i apoptoza kolorektalnoy adenokartsinomyi [Comparative immunohistochemical study of proliferation and apoptosis in colorectal adenocarcinoma]. Patolohiia, 3(38), 65-72. [in Russian].
Hegazy, A., Daoud, S. A., Ibrahim, W. S., El-Atrebi, K., Saker, M., & Abdel-Wahab, N. (2014) Role of Ki-67, P53 and Bcl-2 in Advanced Colorectal Carcinoma (Histopathological and Immunohistochemical Study). Academic Journal of Cancer Research, 7(3), 168–72.
Melling, N., Kowitz, C., M., Simon, R., Bokemeyer, C., Terracciano, L., Sauter, G., et al (2016). High Ki67 expression is an independent good prognostic marker in colorectal cancer. Journal of Clinical Pathology, 69, 209–14.
Xiao, R., Li, C., Chai, B. (2015) miRNA-144 suppresses proliferation and migration of colorectal cancer cells through GSPT1. Biomedicine & Pharmacotherapy,75, 138-144.
Yin, Y., Zhang, B., Wang, W., Fei, B., Quan, C., Zhang, J., Song, M., Bian, Z., Wang, Q., Ni, S., Hu, Y., Mao, Y., Zhou, L., Wang, Y., Yu, J., Du, X., Hua, D., Huang, Z. (2014) miR-204-5p inhibits proliferation and invasion and enhances chemotherapeutic sensitivity of colorectal cancer cells by downregulating RAB22A. Clinical cancer research, 20 (23), 6187-6199.
Thomas, J., Ohtsuka, M., Pichler, M., Ling, H. (2015) MicroRNAs: Clinical Relevance in Colorectal Cancer. International Journal of Molecular Sciences, 16 (12), 28063-28076.
Rezanejad Bardaji, H., Asadi, M. H., Yaghoobi, M. M. (2018) Long noncoding RNA VIM-AS1 promotes colorectal cancer progression and metastasis by inducing EMT. European Journal of Cell Biology, 7, 1035-1048.
Li, X., Zhou, J., Chen, Z., & Chang, W. (2015). p53 mutations in colorectal cancer – molecular pathogenesis and pharmacological reactivation. World Journal of Gastroenterology, 21(1), 84–93.
Wang, Y., Wu, X. S., He, J., Ma, T., Lei, W., Shen, Z.Y. (2016) A novel TP53 variant (rs78378222 A > C) in the polyadenylation signal is associated with increased cancer susceptibility: evidence from a meta-analysis. Oncotarget, 7 (22), 32854-32865.
Du, L., Kim, J. J., Shen, J., Chen, B., Dai, N. (2017) KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis. Oncotarget, 8 (13), 22175-22186.
Pfeffer, C. M., Singh, A. T. K. (2018) Apoptosis: A Target for Anticancer Therapy. International Journal of Molecular Sciences, 19 (2), 448-454.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
